QURE - uniQure N.V.
| Previous Close | 54.70 |
| Open | 54.63 |
| Bid | 55.97 x 800 |
| Ask | 56.21 x 1100 |
| Day's Range | 53.96 - 56.54 |
| 52 Week Range | 21.98 - 69.60 |
| Volume | 166,179 |
| Avg. Volume | 553,304 |
| Market Cap | 2.096B |
| Beta (3Y Monthly) | 1.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.34 |
| Earnings Date | May 30, 2017 - Jun 2, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 77.92 |
- GlobeNewswire•10 days ago
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 15, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
- Zacks•17 days ago
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
- GlobeNewswire•17 days ago
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 08, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AMT-130, the Company’s gene therapy candidate for the treatment of Huntington’s disease. AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients.
- Simply Wall St.•21 days ago
uniQure N.V. (NASDAQ:QURE): Financial Strength Analysis
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as uniQure N.V. (NASDAQ:QURE) wit...
- GlobeNewswire•27 days ago
uniQure to Participate in Multiple Upcoming Industry Conferences
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 29, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
- Investopedia•2 months ago
10 Stocks For The Gene Therapy Revolution
Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.
- Barrons.com•2 months ago
Why Big Pharma Is Diving Into Gene Therapy
Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors
- GlobeNewswire•2 months ago
uniQure Announces 2018 Financial Results and Highlights Recent Company Progress
~ Initiated Dosing Phase of HOPE-B Pivotal Study of AMT-061 in Hemophilia B ~ ~ Reported Updated Clinical Data from Phase IIb Study of AMT-061 Demonstrating Sustained FIX.
- Zacks•2 months ago
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
- GlobeNewswire•2 months ago
uniQure Presents New Preclinical Data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today presented new preclinical data on AMT-130, its gene therapy candidate for the treatment of Huntington’s disease (HD) at the 14th Annual CHDI Huntington’s disease Therapeutics Conference in Palm Springs, California. “Findings from our preclinical studies illustrate the therapeutic potential of AMT-130 in restoring function to damaged brain cells in Huntington’s disease and providing a safe and sustained reduction of mutant huntingtin protein with a gene therapy candidate that could be applicable to a broad patient population,” stated Sander van Deventer, M.D., Ph.D., chief scientific officer at uniQure.
- Zacks•2 months ago
Biotech ETFs Jump on Roche-Spark Deal
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
- Zacks•2 months ago
Deal on the Way Now that Deadline is Delayed?
Deal on the Way Now that Deadline is Delayed?
- Zacks•2 months ago
5 Gene Therapy Stocks to Enrich Your Portfolio
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
- Motley Fool•2 months ago
2 More Gene Therapy Stocks on Big Pharma's Buyout Radar
Roche's big step into the gene-editing space will spark interest for these two stocks.
- Benzinga•2 months ago
Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal
Roche Holdings AG Basel ADR (OTC: RHHBY )'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE ) has sparked a rally in the latter's shares. The Analysts ...
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced two recent online publications of preclinical studies showing significant silencing, or knockdown, of the mutated gene most commonly known to lead to onset of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two devastating neurodegenerative diseases. The proof-of-concept studies were conducted by uniQure scientists and utilized the Company’s miQURE™ technology, a proprietary, next-generation gene-silencing platform.
- Simply Wall St.•2 months ago
How Does Investing In uniQure N.V. (NASDAQ:QURE) Impact The Volatility Of Your Portfolio?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching uniQure N.V. (NASDAQ:QURE) might wantRead More...
- Reuters•2 months ago
UniQure gene therapy shows rise in blood-clotting protein in trial
UniQure NV said on Friday its gene therapy to treat patients with a blood disorder, hemophilia B, increased the levels of a protein that helps in blood clotting after 12 weeks. The updated data from a mid-stage study showed that all three patients on the therapy, AMT-061, showed increasing and sustained levels of factor IX, which helps stop bleeding through blood clots. Hemophilia B is a genetic disorder where the lack of enough factor IX (FIX) prevents blood from clotting, resulting in severe bleeding.
- GlobeNewswire•2 months ago
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
~ Increases in FIX Activity Sustained at up to 51% of Normal, with Mean FIX of 38% of Normal at Twelve Weeks After Administration ~ ~ None of the Patients Received Factor.
- GlobeNewswire•3 months ago
uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it treated the first patient in its HOPE-B pivotal trial of AMT-061, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. AMT-061 has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and access to Priority Medicines (PRIME) regulatory initiative by the European Medicines Agency. “We are very pleased to have successfully administered AMT-061 to the first patient enrolled in the HOPE-B pivotal trial and mark this as a milestone for the field in advancing a potential one-time treatment for patients with hemophilia B,” said Robert Gut, M.D., Ph.D., chief medical officer of uniQure.
- GlobeNewswire•3 months ago
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 22, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for AMT-130, and the IND is now effective allowing uniQure to begin its planned Phase I/II study. AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients. “The FDA’s clearance of our IND for AMT-130 is a significant milestone for Huntington’s disease patients and an important event in the field of gene therapy,” said Matt Kapusta, chief executive officer at uniQure.
Insider Monkey•4 months agoUniqure NV (QURE): Hedge Fund Sentiment Unchanged
The market has been volatile as the Federal Reserve continues its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points through November 16th. SEC filings and hedge fund […]
